Compare PPG Industries, Inc. (PPG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs TG Therapeutics Inc — how do they compare? PPG Industries, Inc. trades at $107.4 (market cap $24.39B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: PPG Industries, Inc. is far larger — about 2.9× TG Therapeutics Inc's market cap, and PPG Industries, Inc. pays a 2.7% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PPG | TGTX | |
|---|---|---|
Market Cap | $24.39B | $8.53B |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $59.06 |
52-Week Low | $94.34 | $26.94 |
Enterprise Value | $30.26B | $8.74B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $109.72, down 2.5% today, with a bearish technical signal and mixed earnings history. The stock shows solid fundamentals with a P/E of 15.74, net income margin of 9.57%, and a consensus analyst price target of $129.17. Recent news highlights product innovations like the ONE RANGE marine coatings and leadership changes aimed at growth. Cash flow improved in 2025 to $893M net, though 2026 projections show a slight decline.
The outlook is cautiously optimistic, supported by analyst buy ratings (55%) and strong profitability metrics, but risks include volatile earnings performance and economic sensitivity. Near-term resistance at $111 and support at $109 are key levels to watch amid current bearish technical trends.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
